

SHORT CV CHIFFOLEAU ELISE

NAME, QUALIFICATIONS AND CONTACT DETAILS

Elise Chiffolleau, PhD, born on 16/09/1975

Family situation: Single parent

CRCN INSERM UMR 1064

CRTI Centre de Recherche en Transplantation et Immunologie, Nantes, France

Email : elise.chiffolleau@univ-nantes.fr Office : +33 (0)2.44.76.81.89

Co-leader since 2019 of Team 1: Dendritic cells and Immunoregulation
in Transplantation and Immunopathology.



EDUCATION AND EMPLOYMENT

-2009: HDR University of Nantes (Ability to conduct research).

-2005-Pres: CRTI UMR1064 (Nantes, France). Position: Researcher CRCN INSERM.

-2002-2003: U Penn, Dept of Medicine (Philadelphia, USA). Postdoctoral Fellow (Mentor: LA Turka).

-1998-2002: PhD student at INSERM437 (Nantes, France). PhD (Mentor : MC Cuturi).

PEDAGOGICAL RESPONSIBILITY

-Co-Coordinator of the Immunopathology, Immuno-intervention and Transplantation, options of Master 2 BBRT Nantes (40h, 6 ECTS) (2013-present).

TEACHING AND TRAINING

-Master degree course at M2 Biology, Biotechnology and Therapeutical Research (BBRT), University of Nantes, Department of Sciences (2013-present) and at Master 1 Biological and Medical Sciences, University of Nantes, Department of Medicine (2015-present).

-Training of 6 PhD candidates and of numerous Master and license students.

-Jury member of thesis defenses at the University of Toulouse (2016, 2020), Tours (2019), Poitiers (2019), Paris Sorbonne (2018), Lyon (2016) and Nantes (2014).

-Permanent jury at Master 2 BBRT at the University of Nantes (2013-present).

PATENTS

-Methods and pharmaceutical compositions for promoting T cells response, EP16306381 21/10/2016 (filed patent WO/2018/073440, co-assignment to OSE Immunotherapeutics).

-Methods for the detection of cells and molecules interacting with receptor CLEC-1, in particular for the detection of CLEC-1 endogenous ligand, EP 19306584.4 05/12/2019.

-Anti-CLEC-1 antibodies and antigen-binding fragment thereof, EP 19306583.6 05/12/2019.

PARTICIPATION IN INSTITUTIONAL COMMITTEES (2015-2020)

-Jury member of "Prime d'Encadrement Doctoral et de Recherche" PEDR INSERM 2020.

-Scientific council of University of Medicine, Nantes 2020.

EDITORIAL ACTIVITY (2015-2020)

Review Editor for Frontiers in Medicine section Translational Medicine.

REVIEWING ACTIVITY (2015-2020)

Science Translational Medicine, JCI Insight, American Journal of Transplantation, Frontiers in Immunology, European Journal of Immunology, Scientific Reports, Plos One, Transplantation, Oncoimmunology, Oncotarget, Frontiers in Medicine, Theranostics, Cellular Physiology and Biochemistry, Cell communication and Signalling, Immunology, International Immunopharmacology, Mediators of Inflammation, Transplantation international, DNA and Cell Biology, Journal of International Medical Research.

GRANT EVALUATION (2015-2020)

Fond de la Recherche Scientifique (Belgium) (2015-2020), PSL University of Paris Valorisation & Qlife (2020).

ORGANIZATION OF MEETING (2015-2020)

-52nd annual meeting of the French Society for Immunology, Nantes, France, 2019.
-22nd Nantes Transplantation congress "Immunotherapies in transplantation & cancer", Nantes, 2017.
-Session moderation: 2nd Labex IGO meeting, Nantes, France 2016, 52nd annual meeting of the French Society for Immunology, Nantes, France, 2019.

HOSPITAL RESEARCH CONTRACT

Vacation contract 2010-2018 on transplantation tolerance.

INDUSTRIAL AND R&D CONTRACTS (2015-2021)

-OSE Immunotherapeutics 25k€ (2016-2017), 156k€ (2018-2021), CIFRE fellowship (2018-ongoing)

ACADEMIC RESEARCH GRANTS (2015-2020):

-Fondation du Rein 2015-2017, 30k€,
-Agence de la Biomédecine 2015-2018, 30k€,
-Ligue contre le Cancer 2019 25k€, 2020, 10 k€,
-Labex IGO 2018-2020, 84k€,
-ANR PRCE C-LECT-INHIB 2018-2021, 326k€.

PRIZE AND HONOURS

-Prize "Don de vie, don du soi" Fondation du rein (2015), Prize "Mentee-Mentor" Basic Science Symposium of the Transplant Science Committee (2013), Prize "Victor et Erminia Mesclé" Fondation pour la Recherche médicale (2007), Prize Société Francophone de Transplantation "Best Master 2" (1998).

PUBLICATIONS (2015-2020) out of a total of 64; H-INDEX: 25

- 1- Drouin M, Saenz J, Evrard B, Gauttier V, Teppaz G, Lopez-Robles MD, Louvet C, Poirier N, Chiffolleau E. CLEC-1 suppress dendritic cell antigen presentation and is a novel myeloid immune checkpoint target for cancer immunotherapy. Cancer Research 2020, Aug Volume: 80 Issue: 16 Supplement: S,. DOI: 10.1158/1538-7445.
- 2- Gauttier V, Drouin M, Saenz J, Evrard B, Mary C, Teppaz G, Desalle A, Thepenier V, Wilhelm E, Poirier N, Chiffolleau E. CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy

- controlling damaged and tumor cells phagocytosis. Cancer Research 2020, Aug Volume: 80 Issue: 16 Supplement: S, DOI: 10.1158/1538-7445.
- 3- Drouin M, Saenz J, Chiffolleau E. C-Type Lectin-Like Receptors: Head or Tail in Cell Death Immunity. Front Immunol. 2020;Feb 11:251. PMID: 32133013
 - 4- Marín E, Bouchet-Delbos L, Renoult O, Louvet C, Nerriere-Daguin V, Managh AJ, Even A, Giraud M, Vu Manh T-P, Aguesse A, Bériou G, Chiffolleau E, Alliot-Licht B, Prieur X, Croyal M, Hutchinson JA, Obermajer N, Geissler EK, Vanhove B, Blancho G, Dalod M, Josien R, Pecqueur C, Cuturi MC, Moreau A. Human Tolerogenic Dendritic Cells Regulate Immune Responses through Lactate Synthesis. Cell Metab. 2019 Dec 3;30(6):1075-1090.e8. PMID: 31801055
 - 5- Chiffolleau E. C-Type Lectin-Like Receptors As Emerging Orchestrators of Sterile Inflammation Represent Potential Therapeutic Targets. Front Immunol. 2018 Feb 15;9:21. PMID: 29497419
 - 6- Lopez Robles MD, Pallier A, Huchet V, Le Texier L, Remy S, Braudeau C, Delbos L, Moreau A, Louvet C, Brosseau C, Royer PJ, Magnan A, Halary F, Josien R, Cuturi MC, Anegon I, Chiffolleau E. Cell-surface C-type lectin-like receptor CLEC-1 dampens dendritic cell activation and downstream Th17 responses. Blood Adv. 2017 Mar 28;1(9):557–568. PMID: 29296975
 - 7- Durand J, Huchet V, Merieau E, Usal C, Chesneau M, Remy S, Heslan M, Anegon I, Cuturi MC, Brouard S and Chiffolleau E. Regulatory B Cells with a Partial Defect in CD40 Signaling and Overexpressing Granzyme B Transfer Allograft Tolerance in Rodents. J Immunol. 2015 Nov 15;195(10):5035-44.
 - 8- Chesneau M, Michel L, Dugast E, Chenouard A, Baron D, Pallier A, Durand J, Braza F, Guerif P, Laplaud DA, Soullou JP, Giral M, Degauque N, Chiffolleau E and Brouard S. Tolerant Kidney Transplant Patients Produce B Cells with Regulatory Properties. J Am SocNephrol. 2015 Feb 2.